Does Puro Work for Man Boobs?

Does Puro work for man boobs? It is a question many men ask when looking for a discreet, non-prescription solution to gynaecomastia. Puro is a topical cream marketed as a remedy for male breast tissue enlargement, but it holds no MHRA marketing authorisation as a medicine. Understanding what causes man boobs, how products like Puro are regulated in the UK, and what evidence-based treatments are actually available is essential before spending money on an unlicensed product or, more importantly, before delaying a proper medical assessment.

What causes man boobs and when might treatment help?

Man boobs (gynaecomastia) are caused by an oestrogen-testosterone imbalance leading to glandular breast tissue growth, and treatment is most beneficial when a reversible cause is identified or significant distress is present. Red-flag features such as a hard lump or nipple discharge require urgent GP assessment.

Man boobs, medically termed gynaecomastia, are caused by an imbalance between oestrogen and testosterone that leads to the growth of glandular breast tissue in males.^[1] This is distinct from pseudogynaecomastia, which is an accumulation of fatty tissue without glandular involvement and is more closely linked to excess body weight.^[1] True gynaecomastia can arise at several life stages, including puberty, middle age and older adulthood, and is often physiological rather than pathological.

Common underlying causes include hormonal changes, certain medicines (such as anabolic steroids, spironolactone, anti-androgens, 5-alpha-reductase inhibitors, some antipsychotics and some antihypertensives), liver disease, hypogonadism and, less commonly, testicular or adrenal tumours.^[1][10] In many adolescent males, pubertal gynaecomastia resolves spontaneously within one to two years without any intervention, as noted in NICE CKS guidance on gynaecomastia.^[1]

Treatment is most likely to be beneficial when gynaecomastia is causing significant physical discomfort, psychological distress or when an identifiable and reversible cause is present. NICE CKS guidance on gynaecomastia and NHS clinical practice both emphasise that a thorough assessment by a GP is the appropriate first step, both to exclude serious underlying conditions and to review any medicines that may be contributing.

Certain features should prompt urgent assessment rather than watchful waiting. These include a hard or irregular unilateral breast lump, nipple retraction or discharge, skin changes or tethering, palpable axillary lymph nodes, or rapid progression of breast tissue changes. These are recognised red-flag features under NICE guidance on suspected cancer recognition and referral (NG12) and warrant prompt GP review and possible urgent referral to a breast clinic. Self-treating without a diagnosis carries the risk of missing a treatable cause or, in rare cases, a more serious condition such as male breast cancer, which, while uncommon, can present similarly.

What is Puro and how is it supposed to work?

Puro is an unlicensed topical cream with no MHRA marketing authorisation and no published clinical trial evidence supporting its effectiveness for gynaecomastia. Topical creams cannot meaningfully reduce true glandular breast tissue regardless of their ingredients.

Puro is a topical cream marketed as a non-prescription remedy for gynaecomastia. It does not hold a marketing authorisation from the MHRA as a medicine. If sold as a topical cream, it is most likely classified as a cosmetic product rather than a licensed pharmaceutical. Cosmetic products in the UK are regulated under the UK Cosmetics Regulation, overseen by the Office for Product Safety and Standards (OPSS), but they are not assessed by the MHRA for medicinal safety, quality or efficacy. This means the therapeutic claims made for such products are not subject to the same regulatory scrutiny as those for MHRA-authorised medicines.

Proponents suggest that Puro works by reducing localised fatty tissue or modulating hormonal activity in breast tissue, often citing plant-derived ingredients. It is worth noting that claims to modulate hormones or treat a medical condition would ordinarily constitute medicinal claims, which under MHRA guidance on borderline products would require a marketing authorisation.^[9] No published, peer-reviewed clinical evidence from robust randomised controlled trials has been identified to support the claim that Puro reduces gynaecomastia in men.

It is also important to distinguish between the two types of man boobs. If the underlying issue is pseudogynaecomastia (fatty tissue), lifestyle changes including diet and exercise may reduce breast size over time. If the issue is true gynaecomastia involving glandular tissue, topical creams are unlikely to have any meaningful effect on that tissue, regardless of the ingredients. Consumers should be cautious about products making therapeutic claims without MHRA authorisation. The Advertising Standards Authority (ASA) has previously taken action against misleading health claims made for products in this category, in line with CAP guidance on medicinal claims for non-medicines.

Are there any side effects or safety concerns to know about?

Because Puro is not MHRA-licensed, its safety profile has not been formally assessed, and there is no standardised adverse effect reporting requirement. The primary risk is delaying appropriate medical assessment of a potentially treatable or serious underlying condition.

Because Puro is not licensed by the MHRA as a medicine, its safety profile has not been formally assessed by the MHRA. If it is sold as a cosmetic, it falls under UK Cosmetics Regulation (OPSS) rather than medicines regulation, and there is no standardised adverse effect reporting requirement comparable to that for MHRA-authorised medicines. This means that consumers have limited reliable information about potential skin reactions, systemic absorption of ingredients or interactions with other medicines or conditions.

Topical products applied to the chest area can cause localised skin reactions including redness, irritation, contact dermatitis or allergic responses, particularly in individuals with sensitive skin or known allergies to plant-derived compounds. Anyone who experiences a skin reaction after applying any topical product should stop use and consult a pharmacist or GP.

From a broader safety perspective, the main concern with using products of this kind for gynaecomastia is the risk of delaying appropriate medical assessment. If an underlying hormonal disorder, medication side effect or, in rare cases, a more serious condition is responsible for breast tissue changes, using an unlicensed topical cream instead of seeking a diagnosis could result in a missed or delayed diagnosis.

If you experience sudden breast pain, a hard lump, nipple discharge or skin changes, contact your GP promptly rather than attempting self-treatment, as these symptoms warrant clinical assessment. Suspected adverse reactions to any product, including those not licensed as medicines, can be reported through the MHRA Yellow Card scheme at yellowcard.^[12][13]mhra.gov.uk. Concerns about the safety of a cosmetic product can also be reported to OPSS or your local Trading Standards service.

What do UK doctors recommend for treating gynaecomastia?

UK doctors recommend a GP consultation first to identify the cause, with options including stopping a causative medicine, watchful waiting for pubertal cases, or specialist referral for persistent or symptomatic gynaecomastia. Off-label medicines such as tamoxifen and surgical options are available in specialist settings.

UK doctors recommend that the first step for any man concerned about breast tissue enlargement is a GP consultation to establish whether the cause is physiological, drug-related or secondary to an underlying condition. In line with NICE CKS guidance on gynaecomastia, the GP will typically take a full medical and medication history, perform a clinical examination including testicular examination, and may arrange blood tests to assess hormone levels (including testosterone, LH, FSH, prolactin and TSH), liver function and, where clinically indicated, tumour markers.^[1]

Where a causative medicine is identified, switching or stopping that medicine under medical supervision may lead to resolution. For physiological pubertal gynaecomastia, watchful waiting is usually appropriate given the high rate of spontaneous resolution. Where red-flag features are present, such as a hard or irregular unilateral lump, nipple retraction or discharge, skin tethering, axillary lymphadenopathy or rapid progression, NICE NG12 criteria support urgent referral to a breast clinic via the two-week-wait pathway.

In cases where gynaecomastia is persistent, symptomatic or causing significant distress, referral to an endocrinologist or breast surgeon may be considered. Medical treatments that have been used in specialist settings include selective oestrogen receptor modulators such as tamoxifen or raloxifene. These are used off-label for this indication in the UK, initiation is specialist-led, and the BNF monographs for tamoxifen and raloxifene provide relevant safety and monitoring information. These medicines are not routinely commissioned by Integrated Care Boards (ICBs) for gynaecomastia. Surgical options, including subcutaneous mastectomy or liposuction, are available privately and, in some cases, through NHS referral where clinical criteria are met, though NHS funding decisions rest with individual ICBs.^[5]

For men exploring whether a clinically supervised approach to weight management or hormonal health might be relevant to their situation, Bolt Pharmacy is a GPhC-registered online pharmacy (GPhC registration covering Great Britain) offering online consultations with prescriber review, where clinically appropriate options can be discussed. Regardless of the route chosen, UK clinical guidance is clear that self-treating with unlicensed topical products is not a substitute for a proper medical assessment, and any persistent or worsening breast changes should be reviewed by a GP.

Frequently Asked Questions